login
Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
FDA Grants Standard Review for GSK's Experimental HPV Vaccine Cervarix
June 01, 2007 at 11:30 AM
Drug News
Cervarix and Merck's HPV vaccine Gardasil have been shown to be 100% effective in preventing infection with HPV strains 16 and 18, which together cause about 70% of cervical cancer cases. Researchers in a 2006 study published in the online edition of the Lancet also found that Cervarix prevented infection with HPV strains 31 and 45, which together with strains 16 and 18 cause more than 80% of cervical cancer cases. GSK in January announced that it would begin a trial to determine whether Cervarix provides better protection against cervical cancer than Gardasil.
The Australian Therapeutic Goods Administration last week granted the first major market license for Cervarix, approving the vaccine for girls and women ages 10 to 45. According to Reuters, the European Medicines Agency could recommend the vaccine next month. FDA will most likely take action on GSK's application in January 2008, according to analysts at Evolution Securities.
Source-Kaiser Family Foundation
LIN/M
|
|
 Comment & Contribute
|
Medwonders Health Network
- Health News Index
|
|
- News Quick Links
| News Categories: |
| » | Report: A Lot of Americans Have No Access to Health Care |
| » | Greece Faces Humanitarian Crisis as Health Care Access Declines in EU, Doctors Group Warns |
| » | HCCI Report Says Rising Prices for Care Responsible for Increased Healthcare Costs for Privately Insured Americans |
| » | Treatment in ED is Based on Children's Insurance Status |
| » | US Spends Most on Healthcare Without Providing Superior Care |
| More Insurance News | |
|
